Karenitecin
Based on 1 publication(s) in Google Scholar
Karenitecin (Cositecan) is a topoisomerase I inhibitor, with potent anti-cancer activity.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.02%
- CAS 番号: 203923-89-1
- 分子式: C25H28N2O4Si
- 分子量:448.59
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-13761
TeniposideTopoisomerase Inhibitor -
HY-17026
GemcitabineDNA Synthesis Inhibitor -
HY-13631
ExatecanTopoisomerase I Inhibitor -
HY-13631A
Exatecan mesylateTopoisomerase I Inhibitor -
HY-13631R
Exatecan (Standard)Topoisomerase I Inhibitor -
HY-15753
EllipticineTopoisomerase Inhibitor -
HY-100309
9-AminocamptothecinTopoisomerase I Inhibitor -
HY-10982
AmonafideTopoisomerase Inhibitor -
HY-13727A
PixantroneTopoisomerase II Inhibitor -
HY-13562A
Banoxantrone dihydrochlorideTopoisomerase II Inhibitor -
HY-13631AG
Exatecan mesylate (GMP)Topoisomerase I Inhibitor -
HY-100875
BisantreneAntitumor Agent
MedChemExpress（MCE）の使用を引用している文献 Karenitecin
MoreTopoisomerase アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
|
Topoisomerase I |
体外実験
Karenitecin is a topoisomerase I inhibitor, with potent anti-cancer activity. Karenitecin inhibits cell growth of A253 cells with IC10, IC50, and IC90 values of 0.01, 0.07, and 0.7 μM after 2 h treatment. Karenitecin induces DNA damage (0.01, 0.07, and 0.7 μM), and increases cyclin E and cdk2 protein expression in A253 cells (0.07, and 0.7 μM). Karenitecin markedly enhances the cyclin B/cdc2-associated kinase activity at low concentration, but slightly suppresses this kinase activity at higher concentration[1]. Karenitecin inhibits several human colon cancer cell lines such as COLO205, COLO320, LS174T, SW1398 and WiDr cells, with IC50s of 2.4 nM, 1.5 nM, 1.6 nM, 2.9 nM, and 3.2 nM, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 203923-89-1
-
性状 Solid
-
分子量 448.59
-
分子式 C25H28N2O4Si
-
Color Light yellow to yellow
-
SMILES
O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C(CC[Si](C)(C)C)C5=CC=CC=C5N=C4C3=C2)=O
-
別名
Cositecan; BNP 1350
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
溶剤 & 溶解度
体外:
DMSO : 3.03 mg/mL (6.75 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (281 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Yin MB, et al. Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol. 2000 Mar;57(3):453-9. [Content Brief]
[2]. Van Hattum AH, et al. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int J Cancer. 2000 Oct 15;88(2):260-6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2292 mL | 11.1460 mL | 22.2921 mL | 55.7302 mL |
| 5 mM | 0.4458 mL | 2.2292 mL | 4.4584 mL | 11.1460 mL |
Karenitecin 関連分類
HY-14812 関連分類
Powered by Bioz